AstraZeneca Earnings Hit By Higher Costs
AstraZeneca reported core earnings for the fourth quarter just short of consensus, but said it expected double-digit percentage growth in 2024.
L’Oreal’s Sales, Profit Miss Expectations on Stagnating Chinese Beauty Market Read More »
BAT Sees Modest Profit Growth After Full-Year Miss Read More »